Related Experiment Video
Updated: Jan 24, 2026

Live-3D-Cell Immunocytochemistry Assays of Pediatric Diffuse Midline Glioma
Published on: November 11, 2021
Epigenetic mechanisms and therapeutic advances in diffuse midline glioma (Review)
Wenbo Wu1, Wenlin Chen1, Wenbin Ma1
1Department of Neurosurgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College Hospital (East), Beijing 100730, P.R. China.
Abstract:
Gliomas are the most common primary malignant tumors of the central nervous system in adults, with diffuse midline gliomas (DMG) being particularly aggressive and associated with inferior survival rate. Notwithstanding advances in molecular diagnostics and epigenetics, the specific pathological mechanisms of DMG remain to be fully elucidated. A series of studies have demonstrated that histone modifications, particularly the histone H3 lysine 27 (H3K27)M mutation, play a pivotal role in the development and progression of DMG. The mutation disrupts histone methylation and acetylation to induce widespread gene expression abnormalities, tumor aggressiveness and treatment resistance. Conventional treatments such as surgery, local radiotherapy and chemotherapy offer limited efficacy. However, emerging precision therapies targeting histone mutations, epigenetic modifications and innovative immunotherapies show promise in improving outcomes. The present study provided a comprehensive overview of the molecular mechanisms, epigenetic characteristics and the latest therapeutic advances in DMG. By investigating the H3K27M mutation and its associated epigenetic mechanisms, the present review aimed to establish theoretical frameworks and research avenues for developing precise therapeutic strategies for DMG, thus contributing to advancing the field of personalized medicine.
Insights
Diffuse midline gliomas (DMG) are aggressive brain tumors driven by histone H3K27M mutations. Understanding these epigenetic changes is key to developing targeted therapies for better patient outcomes.
Area of Science:
- Neuro-oncology
- Epigenetics
- Molecular Biology
Background:
- Diffuse midline gliomas (DMG) represent aggressive central nervous system tumors with poor prognosis.
- Despite advances, the precise pathological mechanisms underlying DMG remain incompletely understood.
- Histone H3 lysine 27 (H3K27)M mutations are implicated in DMG development and progression.
Purpose of the Study:
- To provide a comprehensive overview of DMG molecular mechanisms, epigenetic characteristics, and therapeutic strategies.
- To elucidate the role of H3K27M mutations in DMG pathogenesis.
- To identify research avenues for developing precise, personalized medicine approaches for DMG.
Main Methods:
- Literature review and synthesis of existing research on DMG.
- Analysis of molecular and epigenetic data related to H3K27M mutations.
- Evaluation of current and emerging therapeutic strategies for DMG.
Main Results:
- H3K27M mutations disrupt histone methylation and acetylation, leading to aberrant gene expression.
- These epigenetic alterations contribute to tumor aggressiveness and resistance to conventional treatments.
- Emerging therapies targeting epigenetic modifications and immunotherapies show potential.
Conclusions:
- H3K27M mutations are central to DMG pathogenesis, offering a target for precision medicine.
- Further research into epigenetic mechanisms can guide the development of novel therapeutic strategies.
- Advancing personalized medicine is crucial for improving outcomes in patients with DMG.
Related Concept Videos
Epigenetic Regulation
Epigenetic Regulation
X-chromosome...
Diffusion
Diffusion
Review and Preview
Percentiles are a type of fractile that partition data into...
Review and Preview

